Skip to main content
Top
Published in: Clinical Rheumatology 11/2018

01-11-2018 | Original Article

A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population

Authors: Xin Dong, Junfei Zhou, Xiaojuan Guo, Yifan Li, Yuetong Xu, Qiang Fu, Yong Lu, Yi Zheng

Published in: Clinical Rheumatology | Issue 11/2018

Login to get access

Abstract

To characterize the distinctive chest high-resolution computerized tomography (HRCT) features and clinical manifestations of primary Sjögren syndrome (pSS)-related interstitial lung disease (ILD). The demographic data, clinical manifestations, and laboratory and radiological findings of 527 pSS patients were retrospectively analyzed. ILD was defined based on the presences of pulmonary signs in HRCT. Two hundred six of 527 patients were diagnosed as pSS-ILD, and the prevalence was 39.1%. The three most frequent abnormalities in HRCT were reticular pattern (92.7%), ground-glass attenuation (87.4%), and bronchovascular bundle thickening (82%). One hundred twenty-four cases (60.2%) of the pSS-ILD patients had only a single HRCT pattern, which involved 86 non-specific interstitial pneumonitis (NSIP) cases (41.7%), 22 usual interstitial pneumonia (UIP) cases (10.68%), 8 organizing pneumonia (OP) cases (3.9%), and 8 lymphocytic interstitial pneumonia (LIP) cases (3.9%), respectively. Besides, the more important observation was that 82 cases had no less than two HRCT patterns, and NSIP admixed with OP (43.9%), NSIP admixed with UIP (35.4%), and NSIP admixed with LIP (19.5%) were the most frequent. HRCT of pSS-ILD patients demonstrated bilateral infiltrates (99%), with abnormalities predominantly in the lower lobes (89.3%) and subpleural areas (81.1%), and a few lesions were characterized by hilum distributed (8.7%). Pulmonary function tests (PFTs) revealed impaired diffusion capacity for carbon monoxide and total lung capacity, and the rate of small airway lesions in the pSS-ILD patients was 3.5 times higher in patients of pSS. Logistic regression analysis showed that dry cough (OR 59.05), clubbing (OR 6.26), elevated lactate dehydrogenase (OR 21.38) and positive anti-Ro (OR 7.86) were relevant factors of pSS-ILD. ILD is the common pulmonary involvement of pSS and the prevalence of pSS-ILD is 39.1%. The single pattern of NSIP and UIP in HRCT are the commonest, and about 40% of the pSS-ILD patients possess multiple patterns in HRCT. The classification of idiopathic pulmonary fibrosis cannot completely include the pulmonary imaging features of pSS-ILD.
Literature
1.
go back to reference Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data[J]. Rheumatology 52(1):173–179CrossRef Palm O, Garen T, Berge Enger T, Jensen JL, Lund MB, Aalokken TM, Gran JT (2013) Clinical pulmonary involvement in primary Sjogren’s syndrome: prevalence, quality of life and mortality-a retrospective study based on registry data[J]. Rheumatology 52(1):173–179CrossRef
2.
go back to reference Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M (2005) Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study[J]. Am J Resp Crit Care 171(6):632–638CrossRef Ito I, Nagai S, Kitaichi M, Nicholson AG, Johkoh T, Noma S, Kim DS, Handa T, Izumi T, Mishima M (2005) Pulmonary manifestations of primary Sjogren’s syndrome: a clinical, radiologic, and pathologic study[J]. Am J Resp Crit Care 171(6):632–638CrossRef
3.
go back to reference Sebastian A, Misterska-Skora M, Silicki J, Sebastian M, Wiland P (2017) Chest HRCT findings in patients with primary Sjogren’s syndrome[J]. Adv Clin Exp Med 26(7):1101–1106CrossRef Sebastian A, Misterska-Skora M, Silicki J, Sebastian M, Wiland P (2017) Chest HRCT findings in patients with primary Sjogren’s syndrome[J]. Adv Clin Exp Med 26(7):1101–1106CrossRef
4.
go back to reference Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? [J]. Rheumatol Int 30(10):1317–1324CrossRef Yazisiz V, Arslan G, Ozbudak IH, Turker S, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) Lung involvement in patients with primary Sjogren’s syndrome: what are the predictors? [J]. Rheumatol Int 30(10):1317–1324CrossRef
5.
go back to reference Shi JH, Liu HR, Xu WB, Feng RE, Zhang ZH, Tian XL, Zhu YJ (2009) Pulmonary manifestations of Sjogren’s syndrome[J]. Respiration 78(4):377–386CrossRef Shi JH, Liu HR, Xu WB, Feng RE, Zhang ZH, Tian XL, Zhu YJ (2009) Pulmonary manifestations of Sjogren’s syndrome[J]. Respiration 78(4):377–386CrossRef
6.
go back to reference Li X, Xu B, Ma Y, Li X, Cheng Q, Wang X, Wang G, Qian L, Wei L (2015) Clinical and laboratory profiles of primary Sjogren’s syndrome in a Chinese population: a retrospective analysis of 315 patients[J]. Int J Rheum Dis 18(4):439–446CrossRef Li X, Xu B, Ma Y, Li X, Cheng Q, Wang X, Wang G, Qian L, Wei L (2015) Clinical and laboratory profiles of primary Sjogren’s syndrome in a Chinese population: a retrospective analysis of 315 patients[J]. Int J Rheum Dis 18(4):439–446CrossRef
7.
go back to reference Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Resp Crit Care 188(6):733–748CrossRef Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias[J]. Am J Resp Crit Care 188(6):733–748CrossRef
8.
go back to reference Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis 61(6):554–558CrossRef Vitali C, Bombardieri S, Jonsson R et al (2002) Classification criteria for Sjogren’s syndrome: a revised version of the European criteria proposed by the American-European Consensus Group[J]. Ann Rheum Dis 61(6):554–558CrossRef
9.
go back to reference Shiboski CH, Shiboski SC, Seror R et al (2016) American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017 69(1):35–45 Shiboski CH, Shiboski SC, Seror R et al (2016) American College of Rheumatology/European League Against Rheumatism Classification Criteria for primary Sjogren’s syndrome: a consensus and data-driven methodology involving three international patient cohorts[J]. Arthritis Rheumatol, 2017 69(1):35–45
10.
go back to reference Guo X, Bao N, Lei Z et al (2011) Quantitative comparative analysis of high-resolution CT features of idiopathic interstitial pneumonia[J]. Chin J Med 1:11–15 Guo X, Bao N, Lei Z et al (2011) Quantitative comparative analysis of high-resolution CT features of idiopathic interstitial pneumonia[J]. Chin J Med 1:11–15
11.
go back to reference Nannini C, Jebakumar AJ, Crowson CS et al (2013) Primary Sjogren’s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality[J]. BMJ Open 3(11):003569–003576CrossRef Nannini C, Jebakumar AJ, Crowson CS et al (2013) Primary Sjogren’s syndrome 1976-2005 and associated interstitial lung disease: a population-based study of incidence and mortality[J]. BMJ Open 3(11):003569–003576CrossRef
12.
go back to reference Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjogren’s syndrome. Clinical-pathological evaluation and response to treatment[J]. Am J Resp Crit Care, 1996, 154(3 Pt 1):794–799CrossRef Deheinzelin D, Capelozzi VL, Kairalla RA, Barbas Filho JV, Saldiva PH, de Carvalho CR. Interstitial lung disease in primary Sjogren’s syndrome. Clinical-pathological evaluation and response to treatment[J]. Am J Resp Crit Care, 1996, 154(3 Pt 1):794–799CrossRef
13.
go back to reference Garcia-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients[J]. Medicine 81(4):270–280CrossRef Garcia-Carrasco M, Ramos-Casals M, Rosas J et al (2002) Primary Sjogren syndrome: clinical and immunologic disease patterns in a cohort of 400 patients[J]. Medicine 81(4):270–280CrossRef
14.
go back to reference Stojan G, Baer AN, Danoff SK (2013) Pulmonary manifestations of Sjogren’s syndrome[J]. Curr Allergy Asthma Rep 13(4):354–360CrossRef Stojan G, Baer AN, Danoff SK (2013) Pulmonary manifestations of Sjogren’s syndrome[J]. Curr Allergy Asthma Rep 13(4):354–360CrossRef
15.
go back to reference Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006) Interstitial lung disease in primary Sjogren syndrome[J]. Chest 130(5):1489–1495CrossRef Parambil JG, Myers JL, Lindell RM, Matteson EL, Ryu JH (2006) Interstitial lung disease in primary Sjogren syndrome[J]. Chest 130(5):1489–1495CrossRef
16.
go back to reference Pertovaara M, Pukkala E, Laippala P et al (2001) A longitudinal cohort study of Finnish patients with primary Sjogren’s syndrome: clinical, immunological, and epidemiological aspects[J]. Ann Rheum Dis 60(5):467–472CrossRef Pertovaara M, Pukkala E, Laippala P et al (2001) A longitudinal cohort study of Finnish patients with primary Sjogren’s syndrome: clinical, immunological, and epidemiological aspects[J]. Ann Rheum Dis 60(5):467–472CrossRef
17.
go back to reference Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A, de Vita S, Gerli R, Valesini G, Bombardieri S (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients[J]. Rheumatology 53(5):839–844CrossRef Baldini C, Pepe P, Quartuccio L, Priori R, Bartoloni E, Alunno A, Gattamelata A, Maset M, Modesti M, Tavoni A, de Vita S, Gerli R, Valesini G, Bombardieri S (2014) Primary Sjogren’s syndrome as a multi-organ disease: impact of the serological profile on the clinical presentation of the disease in a large cohort of Italian patients[J]. Rheumatology 53(5):839–844CrossRef
18.
go back to reference Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S (2016) Pulmonary manifestations of Sjogren’s syndrome[J]. Eur Respir Rev 25(140):110–123CrossRef Flament T, Bigot A, Chaigne B, Henique H, Diot E, Marchand-Adam S (2016) Pulmonary manifestations of Sjogren’s syndrome[J]. Eur Respir Rev 25(140):110–123CrossRef
19.
go back to reference Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome[J]. Autoimmun Rev 16(1):48–54CrossRef Roca F, Dominique S, Schmidt J, Smail A, Duhaut P, Lévesque H, Marie I (2017) Interstitial lung disease in primary Sjogren’s syndrome[J]. Autoimmun Rev 16(1):48–54CrossRef
20.
go back to reference Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C (2017) Prevalence and characterization of non-sicca onset primary Sjogren syndrome with interstitial lung involvement[J]. Clin Rheumatol 36(6):1261–1268CrossRef Manfredi A, Sebastiani M, Cerri S, Cassone G, Bellini P, Casa GD, Luppi F, Ferri C (2017) Prevalence and characterization of non-sicca onset primary Sjogren syndrome with interstitial lung involvement[J]. Clin Rheumatol 36(6):1261–1268CrossRef
21.
go back to reference Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K (2003) Pulmonary lesions associated with Sjogren’s syndrome: radiographic and CT findings[J]. Br J Radiol 76(912):880–884CrossRef Matsuyama N, Ashizawa K, Okimoto T, Kadota J, Amano H, Hayashi K (2003) Pulmonary lesions associated with Sjogren’s syndrome: radiographic and CT findings[J]. Br J Radiol 76(912):880–884CrossRef
22.
go back to reference Lin DF, Yan SM, Zhao Y et al (2010) Clinical and prognostic characteristics of 573 cases of primary Sjogren’s syndrome[J]. Chin Med J 123(22):3252–3257PubMed Lin DF, Yan SM, Zhao Y et al (2010) Clinical and prognostic characteristics of 573 cases of primary Sjogren’s syndrome[J]. Chin Med J 123(22):3252–3257PubMed
23.
go back to reference Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L (2008) Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients[J]. Medicine 87(4):210–219CrossRef Ramos-Casals M, Solans R, Rosas J, Camps MT, Gil A, del Pino-Montes J, Calvo-Alen J, Jiménez-Alonso J, Micó ML, Beltrán J, Belenguer R, Pallarés L (2008) Primary Sjogren syndrome in Spain: clinical and immunologic expression in 1010 patients[J]. Medicine 87(4):210–219CrossRef
24.
go back to reference Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group (2014) Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies[J]. Arthritis Care Res 66(5):732–740CrossRef Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG, for the Childhood Myositis Heterogeneity Collaborative Study Group (2014) Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies[J]. Arthritis Care Res 66(5):732–740CrossRef
25.
go back to reference Zheng Y (2015) A new understanding of interstitial lung disease in connective tissue[J]. Chin J Rheumatol 9:577–579 Zheng Y (2015) A new understanding of interstitial lung disease in connective tissue[J]. Chin J Rheumatol 9:577–579
26.
go back to reference Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B (2013) Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren’s syndrome in the absence of anti-SSA/SSB antibodies by ELISA[J]. Rheumatology (Oxford) 52(12):2223–2228CrossRef Mekinian A, Nicaise-Roland P, Chollet-Martin S, Fain O, Crestani B (2013) Anti-SSA Ro52/Ro60 antibody testing by immunodot could help the diagnosis of Sjogren’s syndrome in the absence of anti-SSA/SSB antibodies by ELISA[J]. Rheumatology (Oxford) 52(12):2223–2228CrossRef
27.
go back to reference Sambataro D, Sambataro G, Dal Bosco Y, Polosa R (2017) Present and future of biologic drugs in primary Sjogren’s syndrome[J]. Expert Opin Biol Th 17(1):63–75CrossRef Sambataro D, Sambataro G, Dal Bosco Y, Polosa R (2017) Present and future of biologic drugs in primary Sjogren’s syndrome[J]. Expert Opin Biol Th 17(1):63–75CrossRef
28.
go back to reference Espinosa A, Dardalhon V, Brauner S et al (2009) Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway[J]. Medicine 206(8):1661–1671 Espinosa A, Dardalhon V, Brauner S et al (2009) Loss of the lupus autoantigen Ro52/Trim21 induces tissue inflammation and systemic autoimmunity by disregulating the IL-23-Th17 pathway[J]. Medicine 206(8):1661–1671
29.
go back to reference Kusume K (1991) Lung injury in idiopathic pulmonary fibrosis and measurement of immunoreactive neutrophil elastase and alpha 1-protease inhibitor in blood[J]. Nihon Kyobu Shikkan Gakkai Zasshi 29(10):1254–1260PubMed Kusume K (1991) Lung injury in idiopathic pulmonary fibrosis and measurement of immunoreactive neutrophil elastase and alpha 1-protease inhibitor in blood[J]. Nihon Kyobu Shikkan Gakkai Zasshi 29(10):1254–1260PubMed
30.
go back to reference Zhang Y, Li H, Wu N, Dong X, Zheng Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease[J]. Clin Rheumatol 36(4):817–823CrossRef Zhang Y, Li H, Wu N, Dong X, Zheng Y (2017) Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease[J]. Clin Rheumatol 36(4):817–823CrossRef
31.
go back to reference Yazisiz V, Ozbudak IH, Nizam I, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) A case of primary Sjogren’s syndrome with pulmonary-limited Wegener’s granulomatosis[J]. Rheumatol Int 30(9):1235–1238CrossRef Yazisiz V, Ozbudak IH, Nizam I, Erbasan F, Avci AB, Ozbudak O, Terzioglu E (2010) A case of primary Sjogren’s syndrome with pulmonary-limited Wegener’s granulomatosis[J]. Rheumatol Int 30(9):1235–1238CrossRef
Metadata
Title
A retrospective analysis of distinguishing features of chest HRCT and clinical manifestation in primary Sjögren’s syndrome-related interstitial lung disease in a Chinese population
Authors
Xin Dong
Junfei Zhou
Xiaojuan Guo
Yifan Li
Yuetong Xu
Qiang Fu
Yong Lu
Yi Zheng
Publication date
01-11-2018
Publisher
Springer London
Published in
Clinical Rheumatology / Issue 11/2018
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-018-4289-6

Other articles of this Issue 11/2018

Clinical Rheumatology 11/2018 Go to the issue
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.